The Medical Letter on Drugs and Therapeutics
October 19, 2020
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Timing of Remdesivir for COVID-19
October 19, 2020 (Issue: 1609)Remdesivir (Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use...more
- COVID-19 update: FDA broadens emergency use authorization for Veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19. FDA 2020 August 28. Available at: https://bit.ly/3hUs7fO. Accessed October 8, 2020.
- JH Beigel et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020 October 8 (epub).
- CD Spinner et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324:1048.
- CDC. Duration of isolation and precautions for adults with COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Accessed October 8, 2020.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.